NCT00093028已完成3 期
UARK 2003-35, A Phase III Study of Bortezomib Versus Bortezomib in Two Doses in Combination With Revlimid™ for Patients Relapsing or Progressing on Total Therapy II (UARK 98-026)
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 315
- 试验地点
- 2
- 主要终点
- To find out the effects (good and bad) of treating patients with two new chemotherapy drugs (BORTEZOMIB and REVLIMID).
研究概览
简要总结
The purpose of this study is
- to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™),
- to study how many patients' myeloma responds to treatment on this study, and how many patients survive after this treatment,
- to learn if a patient's genetic makeup before and after treatment can predict which patients will respond to bortezomib and Revlimid™, and to learn more about how the body responds (gene array studies).
详细描述
Two new drugs BORTEZOMIB (Velcade®, PS-341) and REVLIMID (CC-5013) have been shown in recent studies to be effective in patients with advanced multiple myeloma. This study is being done to learn more about the best way to administer these drugs, either alone or in combination. Since it is not known at this time which treatment is the best, participants will be placed by chance in one of the three treatment groups:
- BORTEZOMIB alone
- BORTEZOMIB + REVLIMID
- BORTEZOMIB in a lower dose + REVLIMID.
This chance selection process is called randomization and is often used in research studies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •History of histologically documented Multiple Myeloma (MM) previously enrolled on UARK 98-026 with relapsed or progressive disease after at least one autologous transplant.
- •Patient has measurable disease in which to capture response, defined as: a. Serum M-protein level > or =1.0 gm/dl (10.0 g/L) measured by serum protein electrophoresis or immunoglobulin electrophoresis b. Urinary M-protein excretion > or =200 mg/24 hrs c. Bone marrow plasmacytosis of > or =30% by bone marrow aspirate and/or biopsy d. Serum Free Light Chains (By the Freelite test) > 2X normal.
- •Performance status of < or = 2 as per Zubrod scale, unless PS of 3 based solely on bone pain.
- •Patients must have a platelet count > or = 50,000/mm3, and an ANC of at least 1,000/μl.
- •Patients must have adequate renal function defined as serum creatinine < or =3.0 mg/dl.
- •Patients must have adequate hepatic function defined as serum transaminases and direct bilirubin < or =2 x the upper limit of normal.
- •Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy documented within one week of registration. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
- •Male or female adults of at least 18 years of age.
- •Patients must have signed an IRB-approved written informed consent form and demonstrate willingness to meet follow-up schedule and study procedure obligations
排除标准
- •Chemotherapy or radiotherapy received within the previous 2 weeks.
- •Not previously enrolled on UARK 98-
- •Has received either CC-5013 or bortezomib therapy after discontinuing from UARK 98-
- •Significant neurotoxicity, defined as grade > or = 2 neurotoxicity per NCI Common Toxicity Criteria.
- •Platelet count < 50,000/mm3, or ANC < 1,000/μl
- •POEMS Syndrome
- •Clinically significant hepatic dysfunction as noted by bilirubin or AST >3 times the upper normal limit or clinically significant concurrent hepatitis.
- •New York Hospital Association (NYHA) Class III or Class IV heart failure
- •Myocardial infarction within the last 6 months.
- •Non-secretory MM, unless the patient has measurable lesions on CT, MRI and/or PET.
- •Uncontrolled, active infection requiring IV antibiotics.
- •Patients with a history of treatment for clinically significant ventricular cardiac arrhythmias.
- •Poorly controlled hypertension, diabetes mellitus, or other serious or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol.
- •Pregnant or potential for pregnancy. Women of childbearing potential will have a pregnancy test at screening, and will be required to use a medically approved contraceptive method. Pregnancy testing will be performed prior to administration of each cycle of study drug.
- •Breast-feeding women may not participate.
- •Known hypersensitivity to thalidomide.
结局指标
主要结局
To find out the effects (good and bad) of treating patients with two new chemotherapy drugs (BORTEZOMIB and REVLIMID).
时间窗: 24 months
次要结局
- To learn if a patient's genetic makeup before and after treatment can predict which patients will respond to BORTEZOMIB and REVLIMID, and to learn more about how the body responds (gene array studies).(24 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaB-cell Adult Acute Lymphoblastic Leukemia (ALL)Ph-positive Adult Acute Lymphoblastic Leukemia (ALL)Recurrent Adult Acute Lymphoblastic Leukemia (ALL)T-cell Adult Acute Lymphoblastic Leukemia (ALL)NCT01769209Stanford University18
终止
2 期
Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic MalignanciesMixed Lineage Acute LeukemiaAcute Lymphoid LeukemiaAcute Myeloid LeukemiaNCT02419755St. Jude Children's Research Hospital12
已完成
2 期
A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple MyelomaMultiple MyelomaNCT00872521Janssen-Cilag Pty Ltd107
已完成
2 期
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's LymphomaB-Cell LymphomaNCT00054665National Cancer Institute (NCI)50
尚未招募
不适用
A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone(VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma.Multiple Myeloma (Kahler’s disease)NL-OMON28960Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON) P/a HOVON Data CenterErasmus MC - Daniel den HoedPostbus 52013008 AE RotterdamTel: 010 7041560Fax: 010 7041028e-mail: hdc@erasmusmc.nl1,500